Here are the DEF 14A proxy statements from LifeStance Health Group, Inc. (LFST) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow LFST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LFST filings page.
LifeStance Health Group, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 2, 2026. Stockholders will elect two Class II directors (including CEO David Bourdon and director Robert Bessler) to terms ending in 2029, ratify PricewaterhouseCoopers LLP as auditor for 2026, and approve an advisory say‑on‑pay vote.
The record date is April 10, 2026, with 387,827,677 shares of common stock entitled to vote. In 2025, LifeStance reported revenue of $1.42 billion, up 14%, net income of $9.7 million, Adjusted EBITDA of $157.7 million (up 32%), 9.0 million visits and 8,040 clinicians. Executive pay combines base salary, annual bonuses tied mainly to revenue, Adjusted EBITDA and patient satisfaction, plus time‑based and performance‑based RSUs to align leadership with long‑term stockholder value.